Rani Therapeutics Holdings (RANI) Accumulated Expenses (2020 - 2026)

Rani Therapeutics Holdings' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 105.95% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $4.7 million (up 105.95% YoY), while the FY2025 annual figure was $3.9 million, up 1017.0% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $4.7 million, up from $3.9 million in the prior quarter.
• The five-year high for Accumulated Expenses was $4.7 million in Q1 2026, with the low at $353000.0 in Q4 2024.
• The 5-year median for Accumulated Expenses is $2.6 million (2025), against an average of $2.6 million.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses plunged 72.52% in 2022, then surged 1017.0% in 2025.
• Rani Therapeutics Holdings' Accumulated Expenses stood at $394000.0 in 2022, then increased by 26.9% to $500000.0 in 2023, then slipped by 29.4% to $353000.0 in 2024, then soared by 1017.0% to $3.9 million in 2025, then advanced by 19.35% to $4.7 million in 2026.
• Business Quant data shows RANI's Accumulated Expenses at $4.7 million in Q1 2026, $3.9 million in Q4 2025, and $2.1 million in Q3 2025.